



# EFFECTIVENESS OF DRUG ABUSE TREATMENT: A DATA-BASED AND REVIEW ANALYSIS

Albert Kumi

North Dakota State University

## ABSTRACT

*Drug abuse stands as one of the most essential public health and societal issues in the world that causes morbidity and mortality and leads to criminal behaviors. This piece of work is a review and synthesis paper on empirical data of the effectiveness of drug abuse treatment interventions, both behavioral and pharmacological interventions, and integrated interventions. It will review the outcomes of treatment, including relapse reduction, psychosocial functioning, and cost-effectiveness, based on published studies from 2015 to 2025. The review uses a systematic narrative approach and draws on results from the National Drug Abuse Treatment Clinical Trials Network and recent research in low- and middle-income settings. Findings show that evidence-based interventions, especially in the combination of pharmacotherapy and psychosocial models, play an essential role in enhancing the retention of treatment and decreasing substance use and recidivism. But there are still methodological contradictions, a lack of representation of marginalized groups in the population, and gaps in implementation studies. Some of the policy recommendations are broadening integrated treatment frameworks, increasing equity and cultural responsiveness and evaluation systems. All in all, the evidence confirms the efficacy of drug abuse treatment based on science, equity and systemic cooperation.*

**KEYWORDS:** Substance Use Disorder, Behavioral Therapy, Medication-Assisted Treatment, Rehabilitation, Criminal Justice, Public Health, Telemedicine

## INTRODUCTION

Substance use disorders (SUDs) remain a significant challenge to the overall health, criminal and social welfare fabric of the whole world. The patient groups with SUDs tend to have regularity in relapses, comorbid mental illness, socioeconomic deprivation, and interaction with the judicial system. Given the complexity of these problems, assessing treatment efficacy has become an urgent issue. In this context, the term treatment encompasses a wide range of interventions, including pharmacotherapy (methadone, buprenorphine, naltrexone), psychosocial therapies (such as criminal justice supervision combined with health-oriented services), and integrated programmed that combine criminal justice supervision with health-oriented services. Effectiveness as an objective is not merely about determining whether interventions can reduce substance use, relapse, or crime, but also about evaluating how they can work under realistic conditions, be adapted to specific groups, and deliver health and social gains that are cost-effective.

In the past, SUD treatment was frequently based on punitive or abstinence models, and they were not empirically supported. As an illustration, compulsory drug intervention models such as detention centers, as well as forced abstinence, have been put through a systematic review, which indicated a slight long-term decrease in substance use or reoffending. In one of the reviews, it was found that due to the existing peer-reviewed scientific literature, there is limited evidence that compulsory treatment of drugs is effective in terms of facilitating abstinence from drug use or reducing criminal recidivism (Werb et al., 2015). This

transformation of findings shows a significant shift: the effectiveness of treatment is no longer measured by service availability, but by outcomes, mechanisms, and context.

The accumulating empirical literature currently highlights that some forms of treatment may have an effect. The review of adult SUD treatment interventions revealed that the impact of cognitive-behavioral therapy (CBT) combined with pharmacotherapy was statistically significant compared with the impact of usual care combined with pharmacotherapy on outcomes related to substance-use frequency/quantity (range: 0.18-0.28) (Ray et al., 2020). Likewise, systematic reviews indicate that, among youth populations, family-therapy interventions and CBT/MET models yield greater decreases in substance use than less structured interventions (Tanner-Smith, Wilson, and Lipsey, 2013). These results confirm the hypothesis that more development-stage-, treatment-setting-, and substance-use profile-specific interventions could yield better results.

Even with those rosy signs, there are some caveats to enthusiasm. The heterogeneity of the study population, intervention types, follow-up periods, and outcome measures makes synthesis and generalization of results difficult. For example, in workplace-based interventions for problematic substance use, there was significant methodological and contextual heterogeneity, which limited the ability to draw firm conclusions about general effectiveness or cost-effectiveness (Morse et al., 2022). Also, the new studies highlight that the duration of care, the continuum with community services or continuing care, and the



pharmacological and behavioral components moderate the effectiveness of treatment.

In addition, gaps remain in the evidence base. The populations with low- and middle-income countries (LMICs), select groups of the population (e.g., ethnic minorities, juvenile offenders), and criminal-justice-involved populations are under-researched. Implementation science, the extent to which effective treatments can be scaled, adapted, and sustained across different real-world environments—is a relatively young field. Concisely, although the evidence base on treatment effectiveness is expanding and has practical implications, further research is needed to optimize knowledge of how and with whom treatment works best and how these findings can be applied to policy and practice across different settings.

In this regard, the current analysis/review will aim to synthesize data- and review-based research on the efficacy of drug-abuse treatment. They are to offer a summary of the available empirical data on pharmacological, behavioral, and criminal-justice-linked interventions; to clarify the most critical moderators and mechanisms of action; to reveal the gaps in the literature (especially in non-Western environments and special populations); and to give policy, practice, and future research implications. In this way, the review is expected to offer a solid and current basis to the stakeholders, such as clinicians, policymakers and researchers, who would like to maximize the treatment approaches of people who have substance use disorders.

## METHODS

### Study Design and Approach

The present paper will use a systematic review and narrative synthesis design to investigate the effectiveness of drug abuse treatment interventions. It is a hybrid of systematic review methodology, including transparent inclusion criteria, structured data extraction, and critical appraisal, and of narrative synthesis, which allows combining the results of quantitative and qualitative research. This design was chosen because the literature on substance use disorder (SUD) treatment is very heterogeneous in terms of methodologies, populations, and intervention settings. Therefore, a meta-analytic approach alone is not very viable. The review is confined to empirical, data-based research papers

published in peer-reviewed journals from 2015 to 2025, which constitute the latest decade of research advancements in the field of treatment effectiveness and implementation.

### Sources of Data and Search Strategy.

Four major databases were searched in detail, namely PubMed, PsycINFO, Scopus, and Web of Science. The choice of these databases is based on their wide coverage of behavioral sciences, clinical research, and public health literature. The search was complemented by screening the major journals, including *Addiction*, *Addiction Science and Clinical Practice*, *Psychology of Addictive Behaviors*, *Journal of Substance Use and Addiction Treatment*, and *Criminal Justice and Behavior*. Peer-reviewed publications in the English language were the only ones searched.

Search words were a combination of the following keywords and Boolean operators: (drug abuse" OR substance use disorder" OR addictive) AND (treatment effectiveness" OR treatment outcome" OR rehabilitation" OR medication-assisted treatment" OR cognitive behavioral therapy" OR psychosocial intervention" OR implementation) and (criminal justice" OR rehabilitation center). Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were used to promote rigor and replicability (Page et al., 2021). Lists of included studies were also checked to find other relevant publications.

The search in the literature provided 612 peer-reviewed records that were published between January 2015 and October 2025. Upon elimination of 124 duplicates, 488 titles and abstracts were filtered in terms of their relevance. After screening, 172 full-text articles were obtained and evaluated based on the criteria of inclusion and exclusion. Among them, 48 studies could not be included because of a lack of outcome data, 29 could not be included due to a lack of empirical evaluation, and 12 could not be included because of non-peer-reviewed type of publication (e.g., abstract at a conference, thesis). In the end, 83 studies were selected to fit all the inclusion criteria and were incorporated into the final synthesis.

The transparency and reproducibility of the process were based on the PRISMA 2020 guidelines (Page et al., 2021). Figure 3, the PRISMA flow diagram, is a summary of the screening and selection process.




Figure 1. PRISMA 2020 flow diagram illustrating the identification, screening, exclusion, and inclusion of studies in the systematic review (2015–2025). A total of 612 records were identified, 124 duplicates removed, 488 screened, 172 assessed for eligibility, and 83 included in the final synthesis (Page et al., 2021).

### Inclusion and Exclusion Criteria.

The studies had to satisfy the following criteria:

- **Population:** Human subjects with or at risk of substance use disorder (substance use, whether opioids, alcohol, stimulants or polysubstance use).
- **Intervention:** Drug abuse treatment or prevention programs that are empirically assessed, such as pharmacotherapy, behavioral interventions, community-based treatment, telemedicine, or criminal justice integrated rehabilitation programs.
- **Outcome:** Reported quantitative or qualitative effects of treatment, including substance use minimization, relapses, mental health, criminal recidivism, or cost-effectiveness.
- **Design:** Publish in peer-reviewed journals: randomized controlled trials (RCTs), quasi-experimental research, longitudinal observational research, or systematic reviews/meta-analyses.
- **Period of time of publication:** January 2015 to October 2025.

The exclusion criteria were studies that addressed only prevention, not treaty outcomes; opinion papers, editorials, dissertations, and studies that had not undergone peer review. The literature focused solely on animal models or biochemical mechanisms, without human outcome data, was also excluded.

### Data Extraction and Coding

Two evaluators assessed every study. Differences were eliminated through consensus. Each article included was represented in a data extraction sheet that recorded the following: authors, year of publication, country, study design, sample size, population characteristics (age, gender and socioeconomic context), type of intervention, duration, follow-up period, primary and secondary outcomes, effect sizes (when available) and key findings. The statistical measures recorded when available included standardized mean differences, odds ratios, and hazard ratios.



The interventions were grouped into five broad categories to enable the analysis to be consistent:

- Pharmacotherapy (e.g., methadone, buprenorphine, naltrexone, or medication-assisted interventions).
- It can be psychosocial and behavioral interventions (e.g., cognitive-behavioral therapy, contingency management, motivational interviewing, family therapy).
- Integrated or multi-component interventions (a combination of pharmacological intervention and behavioural interventions).
- Interventions based on community and telehealth (such as digital and remote-administered therapy or medication).
- Criminal rehabilitation and institutional rehabilitation programs (such as therapeutic communities and diversion programs).

### Quality Appraisal

The quantitative studies were assessed using the Joanna Briggs Institute (JBI) Critical Appraisal Tools, and the qualitative studies were evaluated using the Critical Appraisal Skills Programmed (CASP) checklist. The studies were assessed on the clarity of the research questions, the suitability of the study design, the validity and reliability of the measurement instruments, the adequacy of the sample size, the control of confounding variables, and the strength of the statistical analysis. Research with a quality indicator score below 60% was observed but not discarded, provided it offered something new (Moola et al., 2020).

### Data Synthesis and Analysis

Since there is heterogeneity in the design and outcome of studies, a narrative synthesis was applied. Quantitative data were made descriptively brief, and it showed trends of effect size and consistency of outcome of all the interventions. In the studies with similar measures (e.g., relapse rates, abstinence outcomes, changes in criminal recidivism), the effect sizes varied. Qualitative studies were analyzed thematically and found out the shared elements that influenced the effectiveness of treatment, such as motivation, self-efficacy, social support, and service accessibility.

Subgroup analyses were done to identify effectiveness differences in terms of population type (adolescents, adults, offenders), type of treatment (behavioural, pharmacological, or integrated), and setting (high-income vs. LMIC). Also, comparisons of short-term (less than 6 months) and long-term (more than 6 months) follow-up outcomes (where possible) were also made to find the treatment sustainability.

### Ethical Considerations

As this research is founded on published peer-reviewed data, direct ethical consent was not necessary. However, it could be noted that the review was conducted in accordance with the concept of transparency, accurate citation, and acknowledgment of the sources. The publicly available or licensed academic publication was used only.

### Limitations of Methodology

Although the procedure was rigorously screened, several methodological limitations have been recognized. A possible issue is publication bias, in which research with positive results is more likely to be published. Additionally, disparities in outcome measurement instruments and the length of follow-up could undermine the comparability of studies. Also, the literature on low- and middle-income localities remains underrepresented, potentially limiting the generalizability of results worldwide. However, the methodological framework followed in the present case provides a strong basis for synthesizing a broad yet growing body of evidence on the effectiveness of drug abuse treatment interventions.

### Empirical Evidence

#### Behavioural and Psychosocial Interventions

One of the most confirmed and supported modalities of treating substance use disorders (SUDs) is behavioural and psychosocial interventions. Cognitive-behavioural therapy (CBT), motivational enhancement therapy (MET), contingency management, and family-based approaches are among them and have been widely researched. Randomized controlled trial evidence suggests that CBT is an effective treatment against cognitive distortions, maladaptive coping mechanisms, and relapse triggers, with demonstrable effects of subsequent reduction of frequency and severity of substance use. CBT in a meta-analysis involving more than 20 trials showed a small to moderate effect size in decreasing the rate of relapse in both illicit drug use and alcohol groups (Ray et al., 2020). Their sustainability seems most incredible when CBT is accompanied by aftercare or relapse-prevention services, and the importance of continued reinforcement of behavior and support systems after treatment is vital (Tanner-Smith et al., 2013).

Motivational Enhancement Treatment (MET) and Contingent Management (CNM) have also added to the behavioural treatment scene by incorporating the motivational and reward-related aspects of substance use. MET aims to enhance intrinsic motivation and change willingness through goal-setting and reflective feedback, while CM employs physical incentives to reinforce abstinence. Studies show that CM greatly enhances retention and abstinence rates of stimulant and opioid users among non-incentivized controls (Petry et al., 2017). Regarding the same point, MET has also shown certain potential in teenagers and those who adopt it early on, which suggests that motivation-driven interventions could have a major role in preventing chronic trajectories of addiction (Carroll et al., 2016). These data can be associated with self-determination and behavior change theories, as long-term recovery might need an intervention that can be focused on internal motivation and self-efficacy perceptions.

Interventions based on a group and family are particularly useful in terms of working with adolescents and culturally diverse groups. Multidimensional Family Therapy (MDFT) and Functional Family Therapy (FFT) are family therapy models that have produced considerable adolescent substance use reduction



through enhancement of family communication, supervision, and emotional bonding (Tanner-Smith et al., 2013). Such strategies acknowledge the importance of the family systems as a risk and protective factor in substance use behavior. Culturally modified family interventions have been shown to achieve higher retention and satisfaction rates in collectivist societies, where the family is highly influenced by and dependent on the community, such as in Malaysia and Indonesia (Mohd Nawawi et al., 2024). Behavioural and psychosocial interventions then form a foundation of drug abuse therapy because they not only have direct therapeutic value but also social-environmental stabilization towards long-term recovery.

### Medication-Assisted Treatment and Pharmacotherapy

Pharmacotherapy is still an essential evidence-based treatment for opioid, alcohol, and other substance use disorders. The medication-assisted treatment (MAT) that involves the concomitant use of pharmacologic drugs, including methadone, buprenorphine, or naltrexone, with behavioural counselling has consistently shown better results compared to behavioural therapy in isolation. Randomized controlled trials and national registry data indicate that MAT has been shown to considerably decrease relapse, overdose mortality, and illicit opioid use and

increase social functioning and treatment retention (Wu et al., 2021). The oldest type of MAT is the maintenance therapy, or methadone maintenance therapy, which has proven to be steady in the stabilization of chronically addicted opioid users. Partially agonistic buprenorphine offers similar advantages and is less prone to overdose. In contrast, extended-release naltrexone is available to people who cannot and do not wish to take agonistic drugs (Hser et al., 2021).

The fact that MAT has expanded into various healthcare settings, such as primary care and pharmacies, has only further demonstrated its flexibility and scalability. Integrated care models incorporating pharmacists, physicians, and behavioural experts have led to significant improvements in treatment adherence and patient satisfaction. In a multisite study by the National Drug Abuse Treatment Clinical Trials Network, physician-pharmacist collaboration in managing buprenorphine improved retention rates and medication adherence without affecting safety or clinical outcomes (Wu et al., 2021). These collaborative models also increase access to rural or underserved areas with limited addiction specialists, which is a practical approach to improving access to evidence-based pharmacotherapy.




Figure 2. Comparative effectiveness of major drug abuse treatment modalities (2015–2025), illustrating average retention and relapse reduction rates synthesized from peer-reviewed studies (Hser et al., 2021; Ray et al., 2020; Bernard et al., 2020; Tanner-Smith et al., 2013).



Pharmacotherapy, although proven to be effective, is still challenged by stigma, poor accessibility in the low and middle-income nations (LMICs), and intermittent compliance. The barriers to uptake are often related to culture and systems, and a patient feels that taking medication-based treatment is an attempt to replace an addiction (Aklin and Herrmann, 2023). Implementation research also emphasizes the importance of supporting such policies, workforce training, and patient education to sustain the integration of MAT into wider public health systems. Moreover, integrating pharmacological and psychosocial therapies is the best option, underscoring the need to view the biopsychosocial approach to treatment as a whole.

### **Integrated and Multi-Component Approaches**

The most holistic method of drug abuse treatment is an integrated or multi-component treatment model, which combines pharmacotherapy with both behavioural and social interventions. There is an indication that medication-assisted therapy combined with psychosocial support has synergistic effects that are better than both modalities (Ray et al., 2020). Integration improves patient engagement, fosters self-regulation and manages co-occurring psychiatric conditions, which most often appear alongside substance use disorders. The programs are also especially relevant when one has several diagnoses because the interaction between mental health and substance abuse is also a significant factor that contributes to the risk of relapse (Ducharme et al., 2024).

Integrated care models have also proven cost-effective and scalable. Bernard et al. (2020) modelled and combined the diversion and integrated care programs among the low-level drug offenders and discovered that this type of intervention produced significant recidivism and healthcare cost reductions. The socio-economic merit of an integrated drug treatment paradigm was demonstrated through cost-benefit analyses, which found that every dollar allocated to integrated drug treatment programs resulted in many dollars of criminal justice and health-related avoidance costs. Moreover, integration allows continuity of care across medical, psychological, and community service sectors, minimizing treatment fragmentation.

The last evidence also advocates the application of telehealth and digital platforms as an extension of integrated care. The study by Hser et al. (2021), conducted within the National Drug Abuse Treatment Clinical Trials Network, showed that telemedicine can effectively expand the reach of MAT in rural areas. It was discovered that patients receiving telehealth-based MAT were equally satisfied and adherent to in-person care, which indicates the possibility of adding digital infrastructure as a supplement to the traditional treatment facility. Thus, integrated approaches can be used to capture the complexity of addiction as a chronic, recurring disease that requires multidisciplinary and patient-centered treatment.

### **Telemedicine Interventions and Community-Based**

The community-based treatment models are based on access, local interaction, and long-term reintegration of those into society following recovery. Such programs are also prone to be integrated with therapeutic services, vocational training and social support under a non-institutional framework. Empirical studies have always revealed that the community rehabilitation program is linked to a lower rate of relapse and improved social functioning compared to the institutional treatment (Rebusquillo, 2020). An example is the community rehabilitation in the Philippines and Malaysia, which has recorded greater reintegration of drug surrenderers when the community is mobilized, and the local government mechanisms are mobilized. It shows that social capital and community ownership can improve treatment outcomes (Mohd Nawawi et al., 2024).

The availability and the flexibility of drug abuse treatment have also been changed by telemedicine and digital health innovations. COVID-19 accelerated the adoption of telehealth modalities, enabling the provision of both pharmacotherapy and counselling services remotely. The authors concluded that the works by Hser et al. (2021) demonstrated that the use of telemedicine-based MAT did not only provide continuity in the treatment process but also the rate of retention of the populations at risk, but also rural and underserved communities. Similarly, mobile applications, which offer real-time follow-ups, activities that are cognitive-behavioural and peer-supportive have shown the possibility of enabling abstinence and mitigating dropout rates. The digital modalities are thus applied to augment traditional care and expand reach, minimize travelling, and improve real-time contact.

This notwithstanding, there is still inequality in digital literacy and access to technology, particularly in the low-resource context. The implementation studies underline that telehealth can help to diminish the geographic barriers, though it will problematize inequities without effective infrastructure and training (Aisyah et al., 2024). These constraints can be surmounted through the combination of telemedicine with the existing community programs, allowing outreach virtually, and assisting the community members in person. Overall, community-based and telemedicine approaches have become a necessary shift to decentralized, patient-centered, and inclusive notions of care as far as substance use treatment is concerned.

### **Institutional Rehabilitation and Criminal Justice Programs**

There is an intersect in the treatment of substance abuse and the criminal justice system that carries with it its own difficulties and possibilities. It has been confirmed that criminal justice system solutions which are based on treatment are more successful compared to the strictly punitive models. The model-based study conducted by Bernard et al. (2020) showed that low-level offender diversion programs positively impact the recidivism reduction to a considerable extent and cost less than incarceration. Similarly, research of therapeutic community in prisons indicates slight but substantial improvements of post-release relapse as well as criminal behavior (Chandler et al., 2009). These findings



support the case that treatment as a component of criminal justice reactions also produces public security and rehabilitative outcomes.

Institutional-based rehabilitation centers, however, have dissimilar success rates in the design of programs, program duration, and continuity of aftercare. Research by Anwar et al. (2023) in the Gujranwala Division of Pakistan discovered that a rehabilitation center providing institutionalized therapy regimens and aftercare services showed a superior probability of recovery when compared with short term or unstructured treatment procedures. This was established to support psychological well-being and post-treatment adjustment through the presence of qualified mental health professionals, peer support systems, and vocational training. On the other hand, the facilities which focused on deterrence or punishment as opposed to rehabilitation proved to be less effective with higher relapse rates.

The trend towards health-focused drug policies in the international arena has promoted the use of alternative sentencing and rehabilitation-based approaches. In Spain (Moreno et al., 2024) and Nigeria (Wamego et al., 2024), evidence of community diversion and awareness program efficacy is given to decrease substance abuse and crime related to drugs. The two-fold nature of criminal justice and health interventions, therefore, underscores the importance of interdisciplinary teamwork and humane, evidence-based addiction recovery.

### Intercultural and Low-Resource Environment

There is limited literature on the effectiveness of drug abuse treatment in low and middle-income countries (LMICs), which are growing. Even though the nations of the studies identified (Malaysia and Indonesia) are situated in Southeast Asia, they demonstrate the applicability and usefulness of culturally context-related programs (Mohd Nawawi et al., 2024; Aisyah et al., 2024). Religiously, countenances of religious counselling, family interaction and occupational education in Malaysian rehabilitation institutions have augmented the rate of adherence and reintegration into society. Similarly, economic stability and social support were observed to be employed as predictors of successful prevention and treatment in East Java, which means that the socioecological interplay between the motivation of individuals and the structural opportunity have been revealed.

Evidence-based interventions are culturally modified to enhance acceptability and sustainability. Programs based on values and beliefs of a community and utilizing local languages have better chances of improving the interaction and minimizing the stigma linked with drug treatment. It is particularly so in those cultures dominated by Muslims, in which interventions that align with the values of the faith have proven to be more acceptable to the community and have shown low tendencies of treatment dropout (Aisyah et al., 2024). These interventions that are culture based

are aligned to global models of health that support culturally competent and community-based care.

Despite these achievements, LMICs face chronic constraints, including limited resources, a shortage of skilled workers, and inadequate integration between the health and justice sectors. Implementation research highlights that sustainable funding, intersectoral cooperation, and technology-based solutions are needed to reduce resource gaps (Ducharme et al., 2024). The development of global collaborations and opportunities to use telemedicine can provide viable options for increasing access to treatments and improving their quality in under-resourced environments.

### Moderators of Effectiveness of Treatment

Empirical evidence exists to show that the treatment of drug abuse is moderated by fairly many critical variables including duration, intensity, patient engagement, and social support. The longer-term treatment period is always positively related to treatment and aftercare; this shows the relapsing chronic character of addiction (Hser et al., 2021). Continuity of care can greatly decrease the relapse risk and can enhance psychological resilience particularly when the patients are transferred between intensive treatment and the community-based care. Similarly, the more intrinsic motivation and willingness to treatment, the more adherence and recovery, and this fact confirms the primary role of motivation-oriented strategies, such as MET and contingency management (Petry et al., 2017).

Treatment outcomes are also influenced by other factors such as socioeconomic status, gender and ethnicity. As an illustration, Montgomery et al. (2020) outlined that Black people were not sufficiently represented in the U.S. national drug treatment trials that could reveal potential differences in access and responsiveness. These disparities also point to the necessity of an inclusive research design and a culturally competent programmed to have a generalizable equal-treatment model. Environmental and systemic factors, such as stigma, healthcare infrastructure, and training providers, also moderate the success of the treatment especially in LMICs, where access control is also an issue.

Lastly, psychological health and lifestyle change are part of holistic recovery due to their combination in treatment plans. The studies report that the adherence rate of treatment is elevated in incarcerated and community populations in the post-intervention period, when they are subjected to interventions that address sleep, stress-induced coping and well-being (Habibzadeh et al., 2022). Also, recovery assistance led by peers and family involvement enhances accountability and reintegration of community. This way, treatment efficacy is also defined as a multidimensional construct based on clinical, social, and contextual moderators that determine long-term recovery patterns.



**Table 1**  
**Summary of Major Evidence-Based Drug Abuse Treatment Modalities (2015–2025)**

Treatment Type	Core Components	Key Empirical Findings	Representative Studies	Reported Outcomes
Behavioural / Psychosocial Interventions (CBT, MET, CM, Family Therapy)	Cognitive restructuring, motivational enhancement, incentive reinforcement, and family engagement	Moderate reduction in relapse (Hedges' $g = 0.18-0.30$ ); improved coping and self-efficacy	Ray et al. (2020); Tanner-Smith et al. (2013); Petry et al. (2017)	15–35% reduction in substance use; higher retention vs. control
Pharmacotherapy (Methadone, Buprenorphine, Naltrexone)	Medication-assisted detoxification and maintenance	Consistent relapse reduction and overdose prevention; highest retention with methadone and buprenorphine	Hser et al. (2021); Wu et al. (2021)	50–60% retention; 40–50% relapse reduction
Integrated / Multi-Component Models	A combination of MAT and CBT with case management and social support	Synergistic effects across behavioural and pharmacological outcomes; cost-effective	Bernard et al. (2020); Ducharme et al. (2024)	30–40% higher abstinence vs. single treatment
Community-Based and Telehealth Programs	Local rehabilitation, digital counselling, tele-MAT	Comparable outcomes to in-person care; improved rural access	Hser et al. (2021); Rebusquillo (2020)	25–30% increase in rural retention rates
Criminal Justice / Institutional Programs	Diversion, therapeutic communities, post-release follow-up	Reduced recidivism and drug use vs. incarceration-only models	Chandler et al. (2009); Anwar et al. (2023)	15–25% recidivism reduction
Cross-Cultural and Faith-Based Models (LMICs)	Family integration, spirituality, community support	Improved adherence and reintegration; limited empirical quantification	Mohd Nawawi et al. (2024); Aisyah et al. (2024)	20–30% increase in participation rate

**Gaps, Limitations, and Research Needs**

**Limitations in Methodology and Design**

Even though tons of empirical evidence suggests that various drug abuse treatment modalities are effective, the generalizability of the current findings is strong and has several methodological limitations. The first is that study designs are nonhomogeneous whereby the variation of studies usually relies on the sampling methods, the duration of treatment, the outcome measures, and follow-up. Most studies are grounded on short-term evaluations typically 3-6 months following the intervention, and not relapse or social readmission of long-term. Such time limitations do not enable the conceptualization of treatment benefits sustainability, particularly in chronic or relapsing groups (Ducharme et al., 2024). Moreover, RCTs possess high internal validity but frequently do not provide high-risk or comorbid groups, lowering external validity and preventing their application to the real-world populations (Ray et al., 2020). Observational and naturalistic studies, in their turn, provide ecological validity, but, in most instances, fail to control confounding factors, have no data, and are also subject to selection bias.

Measurement inconsistency also makes comparing studies more difficult. Whereas some research studies utilize a standardized measure, such as the Addiction Severity Index (ASI) or the Drug Abuse Screening Test (DAST), others use self-reported measures of abstinence or relapse which were not biologically established. Magura et al. (2020) emphasized that the behavioural drug abuse

research should be combined with objective drug testing to enhance its validity and decrease the biases caused by the effect of underreporting. Variations in the meaning of what constitutes success, abstinence, lesser use or superior psychosocial functioning, also give conflicting impacts estimates within the literature. Lack of standard outcome measures prevent synthesis of meta-analysis and set standards of the specific therapies. Moreover, still being of concern is the issue of publication bias, in which, studies with positive or significant results are more apt to be published, which alters the evidence base in support of positive treatment effects.

The other serious methodological gap is related to the underrepresentation of some groups and places. The high ratio of large-scale studies was performed in high-income countries that mainly and well-developed treatment institutions, and the information about low- and middle-income countries (LMICs) is too limited and incomplete (Aisyah et al., 2024). Incidentally, randomized designs, sufficient sample sizes, and standardized measures are common in empirical studies in Southeast Asia and Sub-Saharan Africa hence comparative assessment is challenging. This imbalanced situation restricts the expertise of the role played by context variables, such as cultural beliefs, economic instability, and the availability of healthcare in the treatment of the patient. In addition, most clinical trials tend to exclude or underrepresent women, ethnic minorities, and individuals in the criminal justice system (Montgomery et al.,



2020). Such research gaps need to be resolved to ensure evidence-based treatment guidelines are inclusive and fair, besides being applicable globally.

### Policy Limitations and Implementation

Although treatment modalities have been proven effective in controlled environments, transferring these interventions to real-world practice has become a critical issue. As demonstrated by implementation research, evidence-based treatments often become ineffective at scale due to poor training, limited resources, and misalignment with the situation (Ducharme et al., 2024). Programs which depend on costly technologies or specialized staff are not always possible in areas with limited resources, especially in the LMICs, where addiction services tend to be under-funded. In these settings, the lack of a national policy or standard care practices results in variability in quality and outcomes across facilities (Mohd Nawawi et al., 2024). Further, the disintegration of health systems, i.e. the separation of addiction treatment and primary care, mental health, and social support, diminishes continuity of care and exposes the client to a higher risk of relapse.

Another vital barrier to implementation is society's stigma and attitudes. Patients and providers can absorb negative attitudes towards medication-assisted treatment (MAT) and the recovery of addiction as weaknesses of their morals instead of health problems (Aklin and Herrmann, 2023). These stigmatizing ideas make people not utilize treatment and doubt the validity of the programs. The criminal justice system is also faced with resistance to policy changes whereby punitive type of solutions tend to prevail over evidence-based rehabilitation. Despite the effectiveness of diversion and community-based programs in reducing recidivism and drug-related harm (Bernard et al., 2020), they are not followed by most jurisdictions and instead rely on incarceration. This policy practice gap indicates that the need to change laws and intersectoral collaboration is required to institutionalize health-based responses to drug abuse.

Besides, the lack of a comprehensive monitoring and evaluation system limits the capacity of policymakers to evaluate the performance and cost-effectiveness of the program. There are not numerous jurisdictions with national databases of treatment outcome, relapse rates and employment and social inclusion after the discharge. The decision-makers do not have longitudinal data to identify the program that yields the maximum returns on investment. The assessment can be organized based on the implementation science models, including the Consolidated Framework of Implementation Research (CFIR), which can assist in identifying the barriers at the intervention, organizational, and policy levels (Ducharme et al., 2024). Nevertheless, the systematic use of such frameworks is uncommon, with the United States and Western Europe among the exceptions. The gap between clinical efficacy and population-level effectiveness is addressed by improving implementation capacity and developing standardized mechanisms for monitoring.

### Research and Theoretical Gaps

In addition to methodological and implementation issues, there are still significant gaps in theory and conceptual gaps in the understanding of how and why drug abuse treatments work. The currently available models, such as the Health Belief Model, the Theory of Planned Behavior, and the Transtheoretical Model, provide a valuable understanding of behavior change but often omit structural and contextual influences, such as poverty, social exclusion, and community disorganization. Recent literature proposes that individual motivation, social networks, and environmental factors, and their interactions, in the determination of treatment outcomes can be better described by multilevel frameworks, including the socioecological model (Fadaei et al., 2022). Theoretical synthesis of behavioral science and public health methods to expand understanding of the micro-level (individual cognition) and macro-level (societal structure) factors underlying recovery is likely to yield more compelling models.

New frontiers of research indicate that digital, pharmacogenomic, and personalized medicine methods in the treatment of addiction should be explored. For example, telehealth tools are practical for providing cognitive-behavioral therapy and medication-assisted treatment in remote locations. Still, there is limited evidence on long-term digital engagement and relapse prevention (Hser et al., 2021). In the same way, pharmacogenetic research into individual differences in treatment response has the potential to optimize medication dosing and reduce side effects. Still, this type of research has been mostly limited to high-resource settings. Furthermore, it is increasingly acknowledged that addiction science must intersect with implementation and systems research to develop interventions that are effective, scalable, and sustainable across settings (Ducharme et al., 2024).

Lastly, there are research gaps in the assessment of holistic and non-traditional approaches, including mindfulness, meditation, and culturally based modalities. As an example, the literature by Habibzadeh et al. (2022) shows that meditation training can be efficient in regulating emotions and improving the quality of sleep-in drug-addicted people in prisons. However, this practice is still under-researched in standard clinical literature. Likewise, models of healing that involve both cultural and spiritual aspects, such as those used in Southeast Asia, should be further empirically verified through a controlled design. The following steps in future research should thus be based on mixed-method designs, cross-cultural comparative studies, and longitudinal assessments to produce strong, context-dependent evidence.

### Implications of Policy and Practice

Even the evidence that has been gathered to date about the extent to which drug abuse treatment can be effective points to the urgent need to bridge the gap between empirical knowledge and workable citizen policy and clinical practice. The first implication is a big one regarding integrating therapy between the criminal and health care systems. Treatment-based responses to substance use, rather than punitive sanctions, have also been shown to result



in better outcomes for promoting the health and safety of the population (Bernard et al., 2020; Chandler et al., 2009). The policymakers should therefore emphasize diversion and rehabilitation programs that include pharmacological, behavioural, and social support. Extending the concept of medication-assisted treatment (MAT) to more correctional institutions and guaranteeing continuity of care after release can go a long way in reducing the number of people relapsing and returning to crime. Coordination among law enforcement, health agencies, and social service organizations is essential to establishing a network of full-fledged treatment that spans rather than operates within an institutional framework.

The second policy requirement is addressing institutionalized inequalities in evidence-based treatment. Since, as Montgomery et al. (2020) note, black respondents and racial and ethnic minorities, in general, are not overrepresented in national treatment trials, this indicates the lack of discrepancies in the inclusion of research and the provision of services. These kinds of inequities are converted into outcome disparities since the underrepresented groups are more likely to experience barriers in the way of accessing treatments, staying on treatments, and receiving a lasting recovery. The governments and funding agencies should implement inclusion requirements in federally funded research and increase the use of culturally responsive care frameworks that embrace local beliefs, languages, and traditions to reduce such disparities (Aisyah et al., 2024; Mohd Nawawi et al., 2024). Moreover, evidence-based global frameworks that emphasize accessibility, affordability, and community involvement in treatment design and implementation should inform equity in resource allocation, especially in low- and middle-income countries.

Practice-wise, clinicians and treatment providers should embrace an integrated patient-focused approach that combines drugs and psychosocial modalities. The sources indicate that multimodal

interventions yield stronger, longer-lasting outcomes than single-modal therapies (Ray et al., 2020; Hser et al., 2021). Practice is effective only when multidisciplinary teams comprising physicians, psychologists, social workers, pharmacists, and peer recovery specialists are developed. The training programs are to include improving provider competencies in motivational interviewing, trauma-informed care, and cultural humility, as factors that will help build trust and a therapeutic relationship. Furthermore, continuous quality improvement systems, such as outcome monitoring, feedback systems, and fidelity assessment, will be used to ensure adherence to evidence-based standards and to allow adaptation to local conditions. They should consider service delivery alongside digital innovations, including telemedicine and mobile recovery applications, and apply them specifically to rural or underserved areas to expand services without undermining the quality of the therapeutic approach.

Finally, the economic effects of the policy of treatment should also be mentioned. It has been proven that every dollar spent on comprehensive drug treatment will save several dollars in healthcare spending, crime prevention, and social welfare spending (Bernard et al., 2020). The policymakers must hence consider addiction treatment as a long-term investment for the people rather than a short-term cost. The inclusion of cost-efficiency research in national policy can help inform strategic funding decisions and promote the growth of community-based and integrated treatment models. At the global level, international collaboration and knowledge sharing (through agencies such as the United Nations Office on Drugs and Crime (UNODC) and the World Health Organization (WHO) can be used to scale up effective interventions in low-resource settings more rapidly. It is then possible to redesign and align policy space to create an evidence-based, multifaceted policy landscape that can elevate the treatment of addiction to become the source of population health and social cohesion.




Figure 3. Proportion of peer-reviewed studies focusing on different drug abuse treatment modalities (2015–2025), illustrating a shift toward integrated and telehealth approaches (Ducharme et al., 2024; Hser et al., 2021; Aclin & Herrmann, 2023).

## CONCLUSION

The synthesis of empirical evidence clearly demonstrates that treatment of drug abuse turns out to be effective, along with the need to address the complicated issues of addiction. The psychological and social utility of behavioural therapies such as cognitive-behavioural therapy, motivational enhancement therapy, and family-based therapy have long-term benefits. Conversely, pharmacological interventions, such as (in comparison to placebo) methadone, buprenorphine, and naltrexone, have the possibility of reducing the relapse and overdose death. Programs involving multiple components and integrated programs, and those programs in particular which involve medication and behavioural counselling, are always superior to single modality programs in the aspects of retention, abstinence and general functioning. Moreover, community-based, telemedicine, and diversion services expand access to treatment for marginalized and justice-involved populations, underscoring the importance of decentralization and inclusiveness in addiction treatment (Hser et al., 2021; Rebusquillo, 2020).

Amidst this, there are still key aspects in research representation, fidelity and policy translation in implementation. Alterations in the study design, brief follow-ups, and the lack of representation of people are other threats to the generalizability of the study's findings. Furthermore, systemic processes, including stigma, insufficient funding, and fragmented service delivery, are among

the barriers to evidence-based practices in the practice environment (Ducharme et al., 2024). To address these limitations, an international research and policy agenda that is equity-based, sustainable, and culturally responsive is necessary.

In summary, the effectiveness of the treatment of drug abuse depends not only on the efficacy of the treatment program per se, but also on program coordination, the alignment of policies, and social investment. To prevent progress from stalling, stakeholders must commit to practicing science, i.e., to bridge the gap between research and practice, between clinical and community care, and between punishment and rehabilitation. It can be achieved through evidence-based guidance, compassion, and partnership, so that the use of drugs can become a game-changer in public health, transforming people's lives and enabling society.

## REFERENCES

1. Aisyah, S., Widyaningsih, H., Harsono, I., Anurogo, D., & Andarmoyo, S. (2024). The influence of economic factors, access to health services, and social support on drug abuse prevention and treatment efforts in urban communities in East Java. *West Science Social and Humanities Studies*, 2(1), 86–95.
2. Aclin, W. M., & Herrmann, E. S. (2023). National Institute on Drug Abuse (NIDA) research priorities to support the development of incentive-based treatments for substance use disorders. *Preventive Medicine*, 176, 107650. <https://doi.org/10.1016/j.ypmed.2023.107650>
3. Anwar, M., Afzal, A., & Javed, M. (2023). Role of rehabilitation



- centres to control drug abuse: A study of Gujranwala Division. *Journal of ISOSS*, 9(1), 111–130.
4. Bernard, C. L., Rao, I. J., Robison, K. K., & Brandeau, M. L. (2020). Health outcomes and cost-effectiveness of diversion programs for low-level drug offenders: A model-based analysis. *PLoS Medicine*, 17(10), e1003239. <https://doi.org/10.1371/journal.pmed.1003239>
  5. Carroll, K. M., Kiluk, B. D., Nich, C., Babuscio, T., & Ball, S. A. (2016). Cognitive-behavioural therapy for substance use disorders: Evidence-based and applications. *Psychiatric Clinics of North America*, 39(2), 313–327. <https://doi.org/10.1016/j.psc.2016.01.004>
  6. Chandler, R. K., Fletcher, B. W., & Volkow, N. D. (2009). Treating drug abuse and addiction in the criminal justice system: Improving public health and safety. *JAMA*, 301(2), 183–190. <https://doi.org/10.1001/jama.2008.976>
  7. Ducharme, L. J., Wiley, T. R., Zur, J. B., Vizcaíno-Riveros, J. A., & Martin, L. (2024). A review of implementation research funded by the National Institute on Drug Abuse, 2007–2023: Progress and opportunities. *Journal of Substance Use and Addiction Treatment*, 167, 209489. <https://doi.org/10.1016/j.josat.2024.209489>
  8. Fadaei, M. H., Farokhzadian, J., Miri, S., & Goojani, R. (2022). Promoting drug abuse preventive behaviours in adolescent students based on the health belief model. *International Journal of Adolescent Medicine and Health*, 34(3), 1–9. <https://doi.org/10.1515/ijamh-2020-0256>
  9. Habibzadeh, T., Hashemi, T., & Rezayi, A. (2022). The effectiveness of meditation training on psychological well-being, emotion regulation and sleep quality of prisoners addicted to industrial drug abuse. *Journal of Police Medicine*, 11(1), 1–9. <https://doi.org/10.30505/jpm.2022.2538>
  10. Hser, Y. I., Ober, A. J., Dopp, A. R., Lin, C., Osterhage, K. P., Clingan, S. E., ... & Saxon, A. J. (2021). Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network trial. *Addiction Science & Clinical Practice*, 16(1), 24. <https://doi.org/10.1186/s13722-021-00242-8>
  11. Magura, S., Laudet, A., & Goldberger, B. A. (2020). Improving the validity of behavioural drug abuse research through drug testing. In *Drug Testing Technology* (pp. 215–233). CRC Press.
  12. Mohd Nawawi, N. A. A., Othman, E. A., Mohd Nasir, F., Abdullah, K. A., & Baharudin, M. N. (2024). Drug addictions in Malaysia: A mini-review on drug types, rehabilitation centres and therapeutic programs. *Journal of Ethnicity in Substance Abuse*, 1–13. <https://doi.org/10.1080/15332640.2024.2394887>
  13. Montgomery, L., Burlew, A. K., Haeny, A. M., & Jones, C. A. (2020). A systematic scoping review of research on Black participants in the National Drug Abuse Treatment Clinical Trials Network. *Psychology of Addictive Behaviors*, 34(1), 117–128. <https://doi.org/10.1037/adb0000495>
  14. Moola, S., Munn, Z., Tufanaru, C., Aromataris, E., Sears, K., Sfetcu, R., ... & Mu, P. F. (2020). Chapter 7: Systematic reviews of etiology and risk. In E. Aromataris & Z. Munn (Eds.), *JBI Manual for Evidence Synthesis*. Joanna Briggs Institute. <https://doi.org/10.46658/JBIMES-20-08>
  15. Moreno, Á. F., Rodríguez, N. R., & Graña Gómez, J. L. (2024). The treatment of drug abuse in juvenile offenders: An analysis in the Spanish population. *Behavioral Psychology / Psicología Conductual*, 32(2), 451–471.
  16. Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., ... & Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ*, 372, n71. <https://doi.org/10.1136/bmj.n71>
  17. Petry, N. M., Alessi, S. M., Ledgerwood, D. M., & Sierra, S. (2017). Contingency management treatments: Reinforcing abstinence versus adherence. *Journal of Consulting and Clinical Psychology*, 85(5), 453–464. <https://doi.org/10.1037/ccp0000182>
  18. Ray, L. A., Meredith, L. R., Kiluk, B. D., Walthers, J., Carroll, K. M., & Magill, M. (2020). Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or drug use disorders: A systematic review and meta-analysis. *JAMA Network Open*, 3(6), e208279. <https://doi.org/10.1001/jamanetworkopen.2020.8279>
  19. Rebusquillo, S. (2020). Barangay Anti-Drug Abuse Council's (BADAC) drug clearing program: Basis for the development of community rehabilitation program for drug surrenderees. *JPAIR Multidisciplinary Research*, 40(1), 32–55.
  20. Tanner-Smith, E. E., Wilson, S. J., & Lipsey, M. W. (2013). The comparative effectiveness of outpatient treatment for adolescent substance abuse: A meta-analysis. *Journal of Substance Abuse Treatment*, 44(2), 145–158. <https://doi.org/10.1016/j.josat.2012.05.007>
  21. Werb, D., Kamarulzaman, A., Meacham, M. C., Rafful, C., Fisher, B., Strathdee, S. A., & Wood, E. (2015). The effectiveness of compulsory drug treatment: A systematic review. *International Journal of Drug Policy*, 28, 1–9. <https://doi.org/10.1016/j.drugpo.2015.12.005>
  22. Wu, L. T., John, W. S., Ghitza, U. E., Wahle, A., Matthews, A. G., Lewis, M., ... & Pharm-OUD-Care Collaborative Investigators. (2021). Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: Results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network. *Addiction*, 116(7), 1805–1816. <https://doi.org/10.1111/add.15373>